Home
/
NovaBay Pharmaceuticals, Inc.
/
Financials
/
Quarterly
NovaBay Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NovaBay Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2015
Mar 31, 2015
$46.0K
May 14, 2015
Q3
2014
Sep 30, 2014
$62.0K
Nov 12, 2014
Q2
2014
Jun 30, 2014
$102.0K
Jul 31, 2014
Q1
2015
Mar 31, 2014
$100.0K
May 14, 2015
Q3
2014
Sep 30, 2013
$1.10M
Nov 12, 2014
Q2
2014
Jun 30, 2013
$831.0K
Jul 31, 2014
Q1
2014
Mar 31, 2013
$957.0K
May 1, 2014
Q3
2013
Sep 30, 2012
$3.64M
Nov 14, 2013
Q2
2013
Jun 30, 2012
$871.0K
Aug 1, 2013
Q1
2013
Mar 31, 2012
$1.32M
May 2, 2013
Q3
2012
Sep 30, 2011
$2.77M
Nov 1, 2012
Q2
2012
Jun 30, 2011
$4.53M
Aug 9, 2012
Q1
2012
Mar 31, 2011
$2.49M
May 3, 2012
Q3
2011
Sep 30, 2010
$2.09M
Nov 7, 2011
Q2
2011
Jun 30, 2010
$2.55M
Aug 10, 2011
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$4.09M
Nov 14, 2017
Q2
2017
Jun 30, 2017
$4.12M
Aug 10, 2017
Q1
2017
Mar 31, 2017
$3.70M
May 11, 2017
Q3
2017
Sep 30, 2016
$3.44M
Nov 14, 2017
Q2
2017
Jun 30, 2016
$2.66M
Aug 10, 2017
Q1
2017
Mar 31, 2016
$1.72M
May 11, 2017
Q3
2016
Sep 30, 2015
$1.20M
Nov 10, 2016
Q2
2016
Jun 30, 2015
$1.01M
Aug 11, 2016
Q1
2016
Mar 31, 2015
$538.0K
May 12, 2016
Q3
2015
Sep 30, 2014
$152.0K
Nov 16, 2015
Q2
2015
Jun 30, 2014
$123.0K
Aug 13, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.29M)
Nov 7, 2025
Q3
2025
Jun 30, 2025
($1.92M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($1.92M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
$7.67M
Nov 7, 2025
Q2
2025
Mar 31, 2025
$7.67M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$7.67M
May 15, 2025
Q3
2025
Sep 30, 2024
($1.21M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($1.59M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($1.59M)
Nov 7, 2025
Q2
2025
Mar 31, 2024
($3.21M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($3.21M)
May 15, 2025
Q3
2025
Mar 31, 2024
($3.21M)
Nov 7, 2025
Q3
2024
Sep 30, 2023
($1.76M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($2.04M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($2.04M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($1.74M)
May 9, 2024
Q2
2024
Mar 31, 2023
($1.74M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($1.74M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
($136.0K)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($2.16M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.26M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($1.89M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($3.29M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.70M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($1.62M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.29M)
May 15, 2025
Q3
2024
Sep 30, 2023
($698.0K)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.05M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($1.35M)
May 9, 2024
Q3
2023
Sep 30, 2022
($457.0K)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($2.15M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($2.38M)
May 11, 2023
Q3
2022
Sep 30, 2021
($2.29M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.86M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($1.52M)
May 12, 2022
Q3
2021
Sep 30, 2020
($2.06M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($1.07M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($1.54M)
May 6, 2021
Q3
2020
Sep 30, 2019
($1.71M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($1.38M)
Aug 6, 2020